drugset

drugset / Trial / NCT04061252

A Study of KHK4827 in Subjects With Palmoplantar Pustulosis

NCT04061252 ↗

Phase 3 Completed 126 enrolled Kyowa Kirin, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis

Timeline

Start: 2019-08-10
Primary completion: 2021-08-11
Completion: 2022-08-05

Publications

Okubo Y, Kobayashi S, Murakami M, Sano S, Kikuta N, Ouchi Y, Terui T. Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial. Am J Clin Dermatol. 2024 Sep;25(5):837-847. doi: 10.1007/s40257-024-00876-x. Epub 2024 Jul 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Brodalumab	Monoclonal antibody	210 mg	Subcutaneous

Indications